NASDAQ:TOCA - Tocagen Stock Price, Price Target & More

Tocagen trades on the NASDAQ under the ticker symbol "TOCA."

Tocagen (NASDAQ:TOCA) announced its earnings results on Thursday, May, 10th. The company reported ($0.65) earnings per share (EPS) for the quarter. The firm earned $0.01 million during the quarter. Tocagen had a negative return on equity of 57.09% and a negative net margin of 109,579.49%. View Tocagen's Earnings History.

Tocagen is scheduled to release their next quarterly earnings announcement on Tuesday, August, 7th 2018. View Earnings Estimates for Tocagen.

2 brokerages have issued 1-year price objectives for Tocagen's shares. Their forecasts range from $15.00 to $24.00. On average, they anticipate Tocagen's stock price to reach $19.50 in the next year. View Analyst Ratings for Tocagen.

Some companies that are related to Tocagen include Vectura Group (VEGPF), Abeona Therapeutics (ABEO), GlycoMimetics (GLYC), CymaBay Therapeutics (CBAY), Homology Medicines (FIXX), ANI Pharmaceuticals Inc Common Stock (ANIP), Dicerna Pharmaceuticals (DRNA), Arcus Biosciences (RCUS), Dova Pharmaceuticals (DOVA), Five Prime Therapeutics (FPRX), Rigel Pharmaceuticals (RIGL), Aduro BioTech (ADRO), ChemoCentryx (CCXI), Lannett (LCI) and Odonate Therapeutics (ODT).

(TOCA) raised $80 million in an initial public offering (IPO) on Thursday, April 13th 2017. The company issued 7,300,000 shares at $10.00-$12.00 per share. Leerink Partners, Evercore ISI and Stifel served as the underwriters for the IPO.

Media coverage about TOCA stock has been trending somewhat positive on Friday, according to Accern Sentiment. The research firm rates the sentiment of media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Tocagen earned a media sentiment score of 0.19 on Accern's scale. They also gave media stories about the company an impact score of 45.52 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

Tocagen's stock is owned by a variety of of institutional and retail investors. Top institutional investors include JPMorgan Chase & Co. (2.86%), BVF Inc. IL (2.53%), Northern Trust Corp (0.91%), Russell Investments Group Ltd. (0.41%), Victory Capital Management Inc. (0.24%) and Millennium Management LLC (0.17%). Company insiders that own Tocagen stock include Asha Das, Harry E Gruber, Mark G Foletta and Paul Schimmel. View Institutional Ownership Trends for Tocagen.

TOCA stock was sold by a variety of institutional investors in the last quarter, including BVF Inc. IL, JPMorgan Chase & Co., Northern Trust Corp and Victory Capital Management Inc.. View Insider Buying and Selling for Tocagen.

TOCA stock was purchased by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Millennium Management LLC and Rhumbline Advisers. Company insiders that have bought Tocagen stock in the last two years include Asha Das, Harry E Gruber, Mark G Foletta and Paul Schimmel. View Insider Buying and Selling for Tocagen.

Shares of TOCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of TOCA stock can currently be purchased for approximately $9.25.

Tocagen has a market capitalization of $190.56 million and generates $40,000.00 in revenue each year. The company earns $-38,920,000.00 in net income (profit) each year or ($2.66) on an earnings per share basis. Tocagen employs 67 workers across the globe.

Tocagen's mailing address is 3030 BUNKER HILL STREET SUITE 230, SAN DIEGO CA, 92109. The company can be reached via phone at 858-412-8400 or via email at [email protected]